RWB
GNMX

RMR Wealth Builders’s Aevi Genomic Medicine Inc GNMX Stock Holding History

RMR Wealth Builders’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$0 Buy
+250
New +$34 ﹤0.01% 421

Other funds holding GNMX

AMCA
Arthur M. Cohen & Associates Northbrook, Illinois $640M AUM 26.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

RMR Wealth Builders's GNMX Position: Q4 2019 in Review

RMR Wealth Builders opened a new position in Aevi Genomic Medicine Inc (GNMX) in Q4 2019: 250 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #421 among its holdings.

28 funds tracked by Wall St. Rank hold GNMX as of Q4 2019.

  • RMR Wealth Builders held 250 shares of Aevi Genomic Medicine Inc worth $0 as of Q4 2019.
  • Aevi Genomic Medicine Inc was a new RMR Wealth Builders position in Q4 2019.
  • Aevi Genomic Medicine Inc made up ﹤0.01% of RMR Wealth Builders's portfolio in Q4 2019, its #421 holding.
  • 28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2019.

Based on RMR Wealth Builders's 13F filing for Q4 2019, filed 3 Mar 2020.